nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—CDH5—breast cancer	0.346	0.596	CbGaD
Lenalidomide—TNFSF11—breast cancer	0.199	0.342	CbGaD
Lenalidomide—ABCB1—Toremifene—breast cancer	0.0261	0.223	CbGbCtD
Lenalidomide—PTGS2—breast cancer	0.0193	0.0333	CbGaD
Lenalidomide—ABCB1—Lapatinib—breast cancer	0.019	0.162	CbGbCtD
Lenalidomide—ABCB1—breast cancer	0.0164	0.0283	CbGaD
Lenalidomide—ABCB1—Vinorelbine—breast cancer	0.0106	0.0901	CbGbCtD
Lenalidomide—ABCB1—Tamoxifen—breast cancer	0.00953	0.0813	CbGbCtD
Lenalidomide—ABCB1—Mitoxantrone—breast cancer	0.0093	0.0793	CbGbCtD
Lenalidomide—ABCB1—Gemcitabine—breast cancer	0.00821	0.0701	CbGbCtD
Lenalidomide—ABCB1—Paclitaxel—breast cancer	0.00742	0.0633	CbGbCtD
Lenalidomide—ABCB1—Irinotecan—breast cancer	0.00732	0.0624	CbGbCtD
Lenalidomide—ABCB1—Vinblastine—breast cancer	0.00651	0.0555	CbGbCtD
Lenalidomide—ABCB1—Docetaxel—breast cancer	0.00536	0.0458	CbGbCtD
Lenalidomide—ABCB1—Doxorubicin—breast cancer	0.004	0.0341	CbGbCtD
Lenalidomide—ABCB1—Methotrexate—breast cancer	0.00387	0.033	CbGbCtD
Lenalidomide—CDH5—mammary gland—breast cancer	0.00324	0.0669	CbGeAlD
Lenalidomide—TNFSF11—embryo—breast cancer	0.00294	0.0607	CbGeAlD
Lenalidomide—CDH5—nipple—breast cancer	0.00268	0.0553	CbGeAlD
Lenalidomide—CDH5—embryo—breast cancer	0.00221	0.0457	CbGeAlD
Lenalidomide—CDH5—epithelium—breast cancer	0.0018	0.0373	CbGeAlD
Lenalidomide—TNFSF11—adrenal gland—breast cancer	0.00174	0.0359	CbGeAlD
Lenalidomide—CRBN—nipple—breast cancer	0.0017	0.0352	CbGeAlD
Lenalidomide—TNFSF11—bone marrow—breast cancer	0.00168	0.0347	CbGeAlD
Lenalidomide—CDH5—endometrium—breast cancer	0.00162	0.0334	CbGeAlD
Lenalidomide—TNFSF11—endocrine gland—breast cancer	0.00151	0.0311	CbGeAlD
Lenalidomide—CDH5—uterus—breast cancer	0.00149	0.0308	CbGeAlD
Lenalidomide—CDH5—pituitary gland—breast cancer	0.00146	0.0302	CbGeAlD
Lenalidomide—CDH5—adipose tissue—breast cancer	0.00146	0.0301	CbGeAlD
Lenalidomide—CRBN—embryo—breast cancer	0.00141	0.029	CbGeAlD
Lenalidomide—CDH5—female reproductive system—breast cancer	0.00134	0.0277	CbGeAlD
Lenalidomide—CDH5—adrenal gland—breast cancer	0.00131	0.027	CbGeAlD
Lenalidomide—CDH5—bone marrow—breast cancer	0.00127	0.0261	CbGeAlD
Lenalidomide—CDH5—female gonad—breast cancer	0.00122	0.0252	CbGeAlD
Lenalidomide—CDH5—endocrine gland—breast cancer	0.00113	0.0234	CbGeAlD
Lenalidomide—Thalidomide—FGFR2—breast cancer	0.00106	0.315	CrCbGaD
Lenalidomide—TNFSF11—lymph node—breast cancer	0.00104	0.0215	CbGeAlD
Lenalidomide—CRBN—endometrium—breast cancer	0.00103	0.0212	CbGeAlD
Lenalidomide—CRBN—uterus—breast cancer	0.000947	0.0196	CbGeAlD
Lenalidomide—CRBN—pituitary gland—breast cancer	0.00093	0.0192	CbGeAlD
Lenalidomide—CRBN—adipose tissue—breast cancer	0.000927	0.0191	CbGeAlD
Lenalidomide—CRBN—female reproductive system—breast cancer	0.000852	0.0176	CbGeAlD
Lenalidomide—CRBN—adrenal gland—breast cancer	0.000831	0.0172	CbGeAlD
Lenalidomide—CRBN—bone marrow—breast cancer	0.000804	0.0166	CbGeAlD
Lenalidomide—CDH5—lymph node—breast cancer	0.000784	0.0162	CbGeAlD
Lenalidomide—CRBN—female gonad—breast cancer	0.000775	0.016	CbGeAlD
Lenalidomide—CRBN—endocrine gland—breast cancer	0.000721	0.0149	CbGeAlD
Lenalidomide—Pomalidomide—TNF—breast cancer	0.000528	0.158	CrCbGaD
Lenalidomide—CRBN—lymph node—breast cancer	0.000498	0.0103	CbGeAlD
Lenalidomide—PTGS2—embryo—breast cancer	0.000383	0.0079	CbGeAlD
Lenalidomide—Thalidomide—TNF—breast cancer	0.000341	0.102	CrCbGaD
Lenalidomide—PTGS2—epithelium—breast cancer	0.000312	0.00644	CbGeAlD
Lenalidomide—PTGS2—skin of body—breast cancer	0.000297	0.00613	CbGeAlD
Lenalidomide—Thalidomide—PTGS1—breast cancer	0.000283	0.0845	CrCbGaD
Lenalidomide—PTGS2—endometrium—breast cancer	0.00028	0.00578	CbGeAlD
Lenalidomide—Thalidomide—CYP1A1—breast cancer	0.000259	0.0773	CrCbGaD
Lenalidomide—PTGS2—uterus—breast cancer	0.000258	0.00533	CbGeAlD
Lenalidomide—Pomalidomide—CYP3A4—breast cancer	0.000256	0.0766	CrCbGaD
Lenalidomide—PTGS2—pituitary gland—breast cancer	0.000253	0.00523	CbGeAlD
Lenalidomide—PTGS2—adipose tissue—breast cancer	0.000252	0.00521	CbGeAlD
Lenalidomide—Pomalidomide—PTGS2—breast cancer	0.000251	0.075	CrCbGaD
Lenalidomide—ABCB1—embryo—breast cancer	0.000237	0.00488	CbGeAlD
Lenalidomide—PTGS2—female reproductive system—breast cancer	0.000232	0.00479	CbGeAlD
Lenalidomide—PTGS2—adrenal gland—breast cancer	0.000226	0.00467	CbGeAlD
Lenalidomide—PTGS2—bone marrow—breast cancer	0.000219	0.00452	CbGeAlD
Lenalidomide—Pomalidomide—ABCB1—breast cancer	0.000213	0.0638	CrCbGaD
Lenalidomide—PTGS2—female gonad—breast cancer	0.000211	0.00436	CbGeAlD
Lenalidomide—PTGS2—endocrine gland—breast cancer	0.000196	0.00405	CbGeAlD
Lenalidomide—ABCB1—epithelium—breast cancer	0.000193	0.00399	CbGeAlD
Lenalidomide—ABCB1—endometrium—breast cancer	0.000173	0.00357	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—breast cancer	0.000162	0.0483	CrCbGaD
Lenalidomide—ABCB1—uterus—breast cancer	0.00016	0.00329	CbGeAlD
Lenalidomide—ABCB1—pituitary gland—breast cancer	0.000157	0.00323	CbGeAlD
Lenalidomide—ABCB1—adipose tissue—breast cancer	0.000156	0.00322	CbGeAlD
Lenalidomide—ABCB1—female reproductive system—breast cancer	0.000143	0.00296	CbGeAlD
Lenalidomide—ABCB1—adrenal gland—breast cancer	0.00014	0.00289	CbGeAlD
Lenalidomide—PTGS2—lymph node—breast cancer	0.000136	0.0028	CbGeAlD
Lenalidomide—ABCB1—bone marrow—breast cancer	0.000135	0.0028	CbGeAlD
Lenalidomide—ABCB1—female gonad—breast cancer	0.000131	0.00269	CbGeAlD
Lenalidomide—ABCB1—endocrine gland—breast cancer	0.000121	0.00251	CbGeAlD
Lenalidomide—ABCB1—lymph node—breast cancer	8.39e-05	0.00173	CbGeAlD
Lenalidomide—Dysgeusia—Methotrexate—breast cancer	1.1e-05	6.41e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Docetaxel—breast cancer	1.1e-05	6.4e-05	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—breast cancer	1.1e-05	6.4e-05	CcSEcCtD
Lenalidomide—Dyspnoea—Capecitabine—breast cancer	1.1e-05	6.4e-05	CcSEcCtD
Lenalidomide—Fatigue—Docetaxel—breast cancer	1.1e-05	6.4e-05	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—breast cancer	1.1e-05	6.39e-05	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—breast cancer	1.1e-05	6.39e-05	CcSEcCtD
Lenalidomide—Nausea—Irinotecan—breast cancer	1.09e-05	6.37e-05	CcSEcCtD
Lenalidomide—Nausea—Mitoxantrone—breast cancer	1.09e-05	6.37e-05	CcSEcCtD
Lenalidomide—Immune system disorder—Epirubicin—breast cancer	1.09e-05	6.36e-05	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—breast cancer	1.09e-05	6.35e-05	CcSEcCtD
Lenalidomide—Pain—Docetaxel—breast cancer	1.09e-05	6.34e-05	CcSEcCtD
Lenalidomide—Constipation—Docetaxel—breast cancer	1.09e-05	6.34e-05	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—breast cancer	1.09e-05	6.34e-05	CcSEcCtD
Lenalidomide—Dyspepsia—Capecitabine—breast cancer	1.09e-05	6.32e-05	CcSEcCtD
Lenalidomide—Chills—Epirubicin—breast cancer	1.08e-05	6.32e-05	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—breast cancer	1.08e-05	6.29e-05	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—breast cancer	1.08e-05	6.28e-05	CcSEcCtD
Lenalidomide—Asthenia—Paclitaxel—breast cancer	1.08e-05	6.28e-05	CcSEcCtD
Lenalidomide—Decreased appetite—Capecitabine—breast cancer	1.07e-05	6.24e-05	CcSEcCtD
Lenalidomide—Alopecia—Epirubicin—breast cancer	1.07e-05	6.22e-05	CcSEcCtD
Lenalidomide—Nausea—Gemcitabine—breast cancer	1.07e-05	6.21e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Capecitabine—breast cancer	1.06e-05	6.2e-05	CcSEcCtD
Lenalidomide—Fatigue—Capecitabine—breast cancer	1.06e-05	6.19e-05	CcSEcCtD
Lenalidomide—Pruritus—Paclitaxel—breast cancer	1.06e-05	6.19e-05	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—breast cancer	1.06e-05	6.17e-05	CcSEcCtD
Lenalidomide—Mental disorder—Epirubicin—breast cancer	1.06e-05	6.17e-05	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—breast cancer	1.06e-05	6.16e-05	CcSEcCtD
Lenalidomide—Constipation—Capecitabine—breast cancer	1.05e-05	6.14e-05	CcSEcCtD
Lenalidomide—Pain—Capecitabine—breast cancer	1.05e-05	6.14e-05	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—breast cancer	1.05e-05	6.13e-05	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—breast cancer	1.05e-05	6.13e-05	CcSEcCtD
Lenalidomide—Feeling abnormal—Docetaxel—breast cancer	1.05e-05	6.11e-05	CcSEcCtD
Lenalidomide—Nausea—Fluorouracil—breast cancer	1.05e-05	6.1e-05	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—breast cancer	1.05e-05	6.09e-05	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—breast cancer	1.04e-05	6.08e-05	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—breast cancer	1.04e-05	6.08e-05	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Docetaxel—breast cancer	1.04e-05	6.07e-05	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—breast cancer	1.04e-05	6.05e-05	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—breast cancer	1.04e-05	6.05e-05	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—breast cancer	1.04e-05	6.05e-05	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—breast cancer	1.04e-05	6.04e-05	CcSEcCtD
Lenalidomide—Tension—Epirubicin—breast cancer	1.03e-05	6.02e-05	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—breast cancer	1.03e-05	6e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Paclitaxel—breast cancer	1.03e-05	5.99e-05	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—breast cancer	1.02e-05	5.95e-05	CcSEcCtD
Lenalidomide—Back pain—Epirubicin—breast cancer	1.02e-05	5.93e-05	CcSEcCtD
Lenalidomide—Feeling abnormal—Capecitabine—breast cancer	1.02e-05	5.92e-05	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—breast cancer	1.02e-05	5.91e-05	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—breast cancer	1.01e-05	5.91e-05	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—breast cancer	1.01e-05	5.89e-05	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—breast cancer	1.01e-05	5.89e-05	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—breast cancer	1.01e-05	5.89e-05	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Capecitabine—breast cancer	1.01e-05	5.87e-05	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—breast cancer	1.01e-05	5.87e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Docetaxel—breast cancer	1.01e-05	5.86e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Docetaxel—breast cancer	1.01e-05	5.86e-05	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—breast cancer	1.01e-05	5.86e-05	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—breast cancer	1e-05	5.85e-05	CcSEcCtD
Lenalidomide—Arrhythmia—Doxorubicin—breast cancer	9.99e-06	5.82e-05	CcSEcCtD
Lenalidomide—Dizziness—Paclitaxel—breast cancer	9.94e-06	5.79e-05	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—breast cancer	9.92e-06	5.78e-05	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—breast cancer	9.89e-06	5.76e-05	CcSEcCtD
Lenalidomide—Cough—Methotrexate—breast cancer	9.82e-06	5.72e-05	CcSEcCtD
Lenalidomide—Mental disorder—Doxorubicin—breast cancer	9.8e-06	5.71e-05	CcSEcCtD
Lenalidomide—Urticaria—Capecitabine—breast cancer	9.8e-06	5.71e-05	CcSEcCtD
Lenalidomide—Ill-defined disorder—Epirubicin—breast cancer	9.77e-06	5.69e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Capecitabine—breast cancer	9.75e-06	5.68e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Capecitabine—breast cancer	9.75e-06	5.68e-05	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—breast cancer	9.74e-06	5.67e-05	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—breast cancer	9.74e-06	5.67e-05	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—breast cancer	9.73e-06	5.67e-05	CcSEcCtD
Lenalidomide—Agitation—Epirubicin—breast cancer	9.67e-06	5.63e-05	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—breast cancer	9.6e-06	5.59e-05	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—breast cancer	9.58e-06	5.58e-05	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—breast cancer	9.58e-06	5.58e-05	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—breast cancer	9.58e-06	5.58e-05	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—breast cancer	9.56e-06	5.57e-05	CcSEcCtD
Lenalidomide—Vomiting—Paclitaxel—breast cancer	9.55e-06	5.56e-05	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—breast cancer	9.54e-06	5.55e-05	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	9.51e-06	5.54e-05	CcSEcCtD
Lenalidomide—Malaise—Epirubicin—breast cancer	9.49e-06	5.53e-05	CcSEcCtD
Lenalidomide—Rash—Paclitaxel—breast cancer	9.47e-06	5.52e-05	CcSEcCtD
Lenalidomide—Dermatitis—Paclitaxel—breast cancer	9.47e-06	5.51e-05	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—breast cancer	9.46e-06	5.51e-05	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—breast cancer	9.46e-06	5.51e-05	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—breast cancer	9.46e-06	5.51e-05	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—breast cancer	9.44e-06	5.5e-05	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—breast cancer	9.42e-06	5.49e-05	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—breast cancer	9.42e-06	5.49e-05	CcSEcCtD
Lenalidomide—Headache—Paclitaxel—breast cancer	9.41e-06	5.48e-05	CcSEcCtD
Lenalidomide—Hypersensitivity—Docetaxel—breast cancer	9.38e-06	5.47e-05	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—breast cancer	9.36e-06	5.45e-05	CcSEcCtD
Lenalidomide—Palpitations—Epirubicin—breast cancer	9.3e-06	5.42e-05	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—breast cancer	9.26e-06	5.39e-05	CcSEcCtD
Lenalidomide—Loss of consciousness—Epirubicin—breast cancer	9.25e-06	5.39e-05	CcSEcCtD
Lenalidomide—Cough—Epirubicin—breast cancer	9.19e-06	5.35e-05	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—breast cancer	9.18e-06	5.35e-05	CcSEcCtD
Lenalidomide—Asthenia—Docetaxel—breast cancer	9.14e-06	5.32e-05	CcSEcCtD
Lenalidomide—Infection—Methotrexate—breast cancer	9.12e-06	5.31e-05	CcSEcCtD
Lenalidomide—Hypertension—Epirubicin—breast cancer	9.09e-06	5.29e-05	CcSEcCtD
Lenalidomide—Hypersensitivity—Capecitabine—breast cancer	9.09e-06	5.29e-05	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—breast cancer	9.04e-06	5.26e-05	CcSEcCtD
Lenalidomide—Pruritus—Docetaxel—breast cancer	9.01e-06	5.25e-05	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—breast cancer	9e-06	5.24e-05	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—breast cancer	9e-06	5.24e-05	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—breast cancer	8.99e-06	5.23e-05	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—breast cancer	8.96e-06	5.22e-05	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—breast cancer	8.96e-06	5.22e-05	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—breast cancer	8.96e-06	5.22e-05	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—breast cancer	8.95e-06	5.21e-05	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—breast cancer	8.93e-06	5.2e-05	CcSEcCtD
Lenalidomide—Nausea—Paclitaxel—breast cancer	8.93e-06	5.2e-05	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—breast cancer	8.92e-06	5.19e-05	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	8.9e-06	5.18e-05	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methotrexate—breast cancer	8.87e-06	5.17e-05	CcSEcCtD
Lenalidomide—Discomfort—Epirubicin—breast cancer	8.85e-06	5.16e-05	CcSEcCtD
Lenalidomide—Asthenia—Capecitabine—breast cancer	8.85e-06	5.15e-05	CcSEcCtD
Lenalidomide—Malaise—Doxorubicin—breast cancer	8.78e-06	5.12e-05	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—breast cancer	8.76e-06	5.1e-05	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—breast cancer	8.75e-06	5.1e-05	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—breast cancer	8.75e-06	5.1e-05	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—breast cancer	8.73e-06	5.09e-05	CcSEcCtD
Lenalidomide—Pruritus—Capecitabine—breast cancer	8.72e-06	5.08e-05	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—breast cancer	8.72e-06	5.08e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Docetaxel—breast cancer	8.71e-06	5.08e-05	CcSEcCtD
Lenalidomide—Confusional state—Epirubicin—breast cancer	8.66e-06	5.04e-05	CcSEcCtD
Lenalidomide—Palpitations—Doxorubicin—breast cancer	8.61e-06	5.01e-05	CcSEcCtD
Lenalidomide—Oedema—Epirubicin—breast cancer	8.59e-06	5e-05	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—breast cancer	8.58e-06	5e-05	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—breast cancer	8.56e-06	4.99e-05	CcSEcCtD
Lenalidomide—Infection—Epirubicin—breast cancer	8.53e-06	4.97e-05	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—breast cancer	8.5e-06	4.95e-05	CcSEcCtD
Lenalidomide—Shock—Epirubicin—breast cancer	8.45e-06	4.92e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Capecitabine—breast cancer	8.44e-06	4.91e-05	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—breast cancer	8.42e-06	4.91e-05	CcSEcCtD
Lenalidomide—Dizziness—Docetaxel—breast cancer	8.42e-06	4.91e-05	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—breast cancer	8.41e-06	4.9e-05	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—breast cancer	8.41e-06	4.9e-05	CcSEcCtD
Lenalidomide—Tachycardia—Epirubicin—breast cancer	8.38e-06	4.88e-05	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—breast cancer	8.36e-06	4.87e-05	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—breast cancer	8.34e-06	4.86e-05	CcSEcCtD
Lenalidomide—Hyperhidrosis—Epirubicin—breast cancer	8.3e-06	4.84e-05	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—breast cancer	8.3e-06	4.84e-05	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—breast cancer	8.29e-06	4.83e-05	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—breast cancer	8.29e-06	4.83e-05	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—breast cancer	8.29e-06	4.83e-05	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—breast cancer	8.26e-06	4.81e-05	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—breast cancer	8.24e-06	4.8e-05	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	8.23e-06	4.8e-05	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—breast cancer	8.19e-06	4.77e-05	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—breast cancer	8.19e-06	4.77e-05	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—breast cancer	8.18e-06	4.77e-05	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—breast cancer	8.16e-06	4.75e-05	CcSEcCtD
Lenalidomide—Dizziness—Capecitabine—breast cancer	8.15e-06	4.75e-05	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—breast cancer	8.11e-06	4.72e-05	CcSEcCtD
Lenalidomide—Vomiting—Docetaxel—breast cancer	8.1e-06	4.72e-05	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—breast cancer	8.08e-06	4.71e-05	CcSEcCtD
Lenalidomide—Rash—Docetaxel—breast cancer	8.03e-06	4.68e-05	CcSEcCtD
Lenalidomide—Hypotension—Epirubicin—breast cancer	8.03e-06	4.68e-05	CcSEcCtD
Lenalidomide—Dermatitis—Docetaxel—breast cancer	8.02e-06	4.67e-05	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—breast cancer	8.01e-06	4.67e-05	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—breast cancer	7.98e-06	4.65e-05	CcSEcCtD
Lenalidomide—Headache—Docetaxel—breast cancer	7.98e-06	4.65e-05	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—breast cancer	7.95e-06	4.63e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—breast cancer	7.93e-06	4.62e-05	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—breast cancer	7.91e-06	4.61e-05	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—breast cancer	7.9e-06	4.6e-05	CcSEcCtD
Lenalidomide—Pain—Methotrexate—breast cancer	7.85e-06	4.57e-05	CcSEcCtD
Lenalidomide—Vomiting—Capecitabine—breast cancer	7.84e-06	4.57e-05	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—breast cancer	7.83e-06	4.56e-05	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—breast cancer	7.82e-06	4.55e-05	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—breast cancer	7.8e-06	4.54e-05	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—breast cancer	7.78e-06	4.53e-05	CcSEcCtD
Lenalidomide—Rash—Capecitabine—breast cancer	7.78e-06	4.53e-05	CcSEcCtD
Lenalidomide—Insomnia—Epirubicin—breast cancer	7.77e-06	4.53e-05	CcSEcCtD
Lenalidomide—Dermatitis—Capecitabine—breast cancer	7.77e-06	4.52e-05	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—breast cancer	7.76e-06	4.52e-05	CcSEcCtD
Lenalidomide—Headache—Capecitabine—breast cancer	7.73e-06	4.5e-05	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—breast cancer	7.72e-06	4.5e-05	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—breast cancer	7.71e-06	4.49e-05	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—breast cancer	7.68e-06	4.48e-05	CcSEcCtD
Lenalidomide—Dyspnoea—Epirubicin—breast cancer	7.66e-06	4.46e-05	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—breast cancer	7.64e-06	4.45e-05	CcSEcCtD
Lenalidomide—Anorexia—Doxorubicin—breast cancer	7.58e-06	4.41e-05	CcSEcCtD
Lenalidomide—Nausea—Docetaxel—breast cancer	7.57e-06	4.41e-05	CcSEcCtD
Lenalidomide—Feeling abnormal—Methotrexate—breast cancer	7.56e-06	4.41e-05	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—breast cancer	7.56e-06	4.4e-05	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—breast cancer	7.51e-06	4.37e-05	CcSEcCtD
Lenalidomide—Decreased appetite—Epirubicin—breast cancer	7.47e-06	4.35e-05	CcSEcCtD
Lenalidomide—Hypotension—Doxorubicin—breast cancer	7.43e-06	4.33e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—breast cancer	7.42e-06	4.32e-05	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—breast cancer	7.41e-06	4.31e-05	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—breast cancer	7.35e-06	4.28e-05	CcSEcCtD
Lenalidomide—Pain—Epirubicin—breast cancer	7.35e-06	4.28e-05	CcSEcCtD
Lenalidomide—Nausea—Capecitabine—breast cancer	7.32e-06	4.27e-05	CcSEcCtD
Lenalidomide—Urticaria—Methotrexate—breast cancer	7.29e-06	4.25e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—breast cancer	7.26e-06	4.23e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—breast cancer	7.26e-06	4.23e-05	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—breast cancer	7.24e-06	4.22e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GSTA2—breast cancer	7.21e-06	9.08e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GPX2—breast cancer	7.21e-06	9.08e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RPS8—breast cancer	7.2e-06	9.07e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RPS7—breast cancer	7.2e-06	9.07e-05	CbGpPWpGaD
Lenalidomide—Insomnia—Doxorubicin—breast cancer	7.19e-06	4.19e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—DKK1—breast cancer	7.14e-06	9e-05	CbGpPWpGaD
Lenalidomide—Paraesthesia—Doxorubicin—breast cancer	7.14e-06	4.16e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—SULT1A1—breast cancer	7.12e-06	8.97e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GPX4—breast cancer	7.12e-06	8.97e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ANGPTL4—breast cancer	7.11e-06	8.96e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ESRRA—breast cancer	7.11e-06	8.96e-05	CbGpPWpGaD
Lenalidomide—Dyspnoea—Doxorubicin—breast cancer	7.09e-06	4.13e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—ALDOA—breast cancer	7.09e-06	8.93e-05	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Epirubicin—breast cancer	7.08e-06	4.12e-05	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—breast cancer	7.07e-06	4.12e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TP53—breast cancer	7.06e-06	8.9e-05	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Epirubicin—breast cancer	7.02e-06	4.09e-05	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—breast cancer	7e-06	4.07e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—JAG2—breast cancer	6.98e-06	8.8e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTA1—breast cancer	6.95e-06	8.76e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—IDH1—breast cancer	6.95e-06	8.76e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—breast cancer	6.95e-06	8.76e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A5—breast cancer	6.94e-06	8.75e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—breast cancer	6.91e-06	8.71e-05	CbGpPWpGaD
Lenalidomide—Decreased appetite—Doxorubicin—breast cancer	6.91e-06	4.02e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—breast cancer	6.89e-06	8.69e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—WNT1—breast cancer	6.88e-06	8.67e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NAT2—breast cancer	6.87e-06	8.67e-05	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—breast cancer	6.86e-06	4e-05	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—breast cancer	6.85e-06	3.99e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—SLC2A2—breast cancer	6.83e-06	8.61e-05	CbGpPWpGaD
Lenalidomide—Urticaria—Epirubicin—breast cancer	6.82e-06	3.97e-05	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—breast cancer	6.8e-06	3.96e-05	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—breast cancer	6.8e-06	3.96e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—breast cancer	6.79e-06	3.96e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—breast cancer	6.79e-06	3.96e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—breast cancer	6.77e-06	8.54e-05	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Methotrexate—breast cancer	6.76e-06	3.94e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—HRAS—breast cancer	6.75e-06	8.51e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HADHB—breast cancer	6.74e-06	8.5e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPI—breast cancer	6.74e-06	8.5e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC2A1—breast cancer	6.7e-06	8.45e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTR—breast cancer	6.69e-06	8.43e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—breast cancer	6.59e-06	8.31e-05	CbGpPWpGaD
Lenalidomide—Asthenia—Methotrexate—breast cancer	6.59e-06	3.84e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—breast cancer	6.58e-06	8.29e-05	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Doxorubicin—breast cancer	6.55e-06	3.81e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—breast cancer	6.53e-06	8.23e-05	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Doxorubicin—breast cancer	6.5e-06	3.79e-05	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—breast cancer	6.49e-06	3.78e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IL6—breast cancer	6.46e-06	8.15e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALDH1A1—breast cancer	6.43e-06	8.11e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALDH7A1—breast cancer	6.43e-06	8.11e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—breast cancer	6.38e-06	8.04e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—breast cancer	6.36e-06	8.02e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—breast cancer	6.33e-06	7.98e-05	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Epirubicin—breast cancer	6.33e-06	3.69e-05	CcSEcCtD
Lenalidomide—Urticaria—Doxorubicin—breast cancer	6.31e-06	3.68e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—breast cancer	6.28e-06	3.66e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—breast cancer	6.28e-06	3.66e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—breast cancer	6.28e-06	3.66e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—breast cancer	6.22e-06	7.85e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HSPA1B—breast cancer	6.22e-06	7.84e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—breast cancer	6.21e-06	7.83e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NME1—breast cancer	6.16e-06	7.77e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ADSL—breast cancer	6.16e-06	7.77e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FHL2—breast cancer	6.16e-06	7.77e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—UMPS—breast cancer	6.16e-06	7.77e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PHGDH—breast cancer	6.16e-06	7.77e-05	CbGpPWpGaD
Lenalidomide—Asthenia—Epirubicin—breast cancer	6.16e-06	3.59e-05	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—NCOA1—breast cancer	6.13e-06	7.73e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—breast cancer	6.13e-06	7.72e-05	CbGpPWpGaD
Lenalidomide—Pruritus—Epirubicin—breast cancer	6.08e-06	3.54e-05	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—breast cancer	6.07e-06	3.54e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—LDHB—breast cancer	6.05e-06	7.62e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HPSE—breast cancer	6.05e-06	7.62e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BRIP1—breast cancer	6.05e-06	7.62e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MED12—breast cancer	6.03e-06	7.6e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—DPYD—breast cancer	6.03e-06	7.6e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PLG—breast cancer	5.98e-06	7.53e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ENO1—breast cancer	5.96e-06	7.52e-05	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—breast cancer	5.96e-06	7.52e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALDOA—breast cancer	5.93e-06	7.48e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—breast cancer	5.9e-06	7.44e-05	CbGpPWpGaD
Lenalidomide—Diarrhoea—Epirubicin—breast cancer	5.88e-06	3.42e-05	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—breast cancer	5.86e-06	3.41e-05	CcSEcCtD
Lenalidomide—Vomiting—Methotrexate—breast cancer	5.84e-06	3.4e-05	CcSEcCtD
Lenalidomide—Rash—Methotrexate—breast cancer	5.79e-06	3.37e-05	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—breast cancer	5.78e-06	3.37e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—NCOA3—breast cancer	5.76e-06	7.26e-05	CbGpPWpGaD
Lenalidomide—Headache—Methotrexate—breast cancer	5.75e-06	3.35e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—breast cancer	5.75e-06	7.24e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HMMR—breast cancer	5.73e-06	7.22e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA3—breast cancer	5.73e-06	7.22e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCC1—breast cancer	5.73e-06	7.22e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC2A2—breast cancer	5.72e-06	7.21e-05	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—breast cancer	5.7e-06	3.32e-05	CcSEcCtD
Lenalidomide—Dizziness—Epirubicin—breast cancer	5.68e-06	3.31e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	5.66e-06	7.14e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF3—breast cancer	5.64e-06	7.11e-05	CbGpPWpGaD
Lenalidomide—Pruritus—Doxorubicin—breast cancer	5.62e-06	3.28e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—MTR—breast cancer	5.6e-06	7.06e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CPT1A—breast cancer	5.6e-06	7.06e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCG2—breast cancer	5.6e-06	7.06e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—JAG1—breast cancer	5.57e-06	7.02e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FASN—breast cancer	5.57e-06	7.02e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARGC1B—breast cancer	5.55e-06	7e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PARP1—breast cancer	5.54e-06	6.99e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—HMOX1—breast cancer	5.51e-06	6.95e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HPGDS—breast cancer	5.5e-06	6.93e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CALCA—breast cancer	5.48e-06	6.9e-05	CbGpPWpGaD
Lenalidomide—Vomiting—Epirubicin—breast cancer	5.46e-06	3.18e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—HBA1—breast cancer	5.46e-06	6.88e-05	CbGpPWpGaD
Lenalidomide—Nausea—Methotrexate—breast cancer	5.45e-06	3.18e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—breast cancer	5.44e-06	3.17e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—breast cancer	5.44e-06	6.85e-05	CbGpPWpGaD
Lenalidomide—Rash—Epirubicin—breast cancer	5.42e-06	3.15e-05	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—breast cancer	5.41e-06	3.15e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—RPS6—breast cancer	5.41e-06	6.82e-05	CbGpPWpGaD
Lenalidomide—Headache—Epirubicin—breast cancer	5.38e-06	3.13e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—FGF4—breast cancer	5.37e-06	6.77e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CXCR4—breast cancer	5.35e-06	6.74e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ACHE—breast cancer	5.33e-06	6.72e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTT1—breast cancer	5.33e-06	6.72e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC2A1—breast cancer	5.29e-06	6.67e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—breast cancer	5.29e-06	6.67e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—breast cancer	5.27e-06	6.65e-05	CbGpPWpGaD
Lenalidomide—Dizziness—Doxorubicin—breast cancer	5.26e-06	3.06e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—CA9—breast cancer	5.24e-06	6.61e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA4—breast cancer	5.24e-06	6.61e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	5.17e-06	6.52e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—breast cancer	5.17e-06	6.52e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TCF7L2—breast cancer	5.16e-06	6.5e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA2—breast cancer	5.11e-06	6.44e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPX2—breast cancer	5.11e-06	6.44e-05	CbGpPWpGaD
Lenalidomide—Nausea—Epirubicin—breast cancer	5.1e-06	2.97e-05	CcSEcCtD
Lenalidomide—Vomiting—Doxorubicin—breast cancer	5.05e-06	2.94e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—SULT1A1—breast cancer	5.05e-06	6.36e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPX4—breast cancer	5.05e-06	6.36e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP17A1—breast cancer	5.05e-06	6.36e-05	CbGpPWpGaD
Lenalidomide—Rash—Doxorubicin—breast cancer	5.01e-06	2.92e-05	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—breast cancer	5.01e-06	2.92e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—ENO1—breast cancer	4.99e-06	6.3e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTGS1—breast cancer	4.99e-06	6.3e-05	CbGpPWpGaD
Lenalidomide—Headache—Doxorubicin—breast cancer	4.98e-06	2.9e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	4.98e-06	6.27e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HSP90AA1—breast cancer	4.97e-06	6.27e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—IDH1—breast cancer	4.93e-06	6.21e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA1—breast cancer	4.93e-06	6.21e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—breast cancer	4.93e-06	6.21e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—breast cancer	4.91e-06	6.19e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2D6—breast cancer	4.9e-06	6.17e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—breast cancer	4.89e-06	6.16e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NAT2—breast cancer	4.87e-06	6.14e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRL—breast cancer	4.84e-06	6.1e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NCOA2—breast cancer	4.81e-06	6.06e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ADAM10—breast cancer	4.77e-06	6.01e-05	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—breast cancer	4.72e-06	2.75e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—FASN—breast cancer	4.66e-06	5.88e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—BCHE—breast cancer	4.64e-06	5.85e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF10—breast cancer	4.64e-06	5.85e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC5A5—breast cancer	4.59e-06	5.78e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—breast cancer	4.49e-06	5.66e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PDGFA—breast cancer	4.48e-06	5.64e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC2A1—breast cancer	4.43e-06	5.58e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NQO1—breast cancer	4.43e-06	5.58e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFBR2—breast cancer	4.41e-06	5.56e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—breast cancer	4.34e-06	5.47e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ITPR1—breast cancer	4.34e-06	5.47e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	4.34e-06	5.47e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP3A4—breast cancer	4.32e-06	5.45e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT5A—breast cancer	4.31e-06	5.44e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB4—breast cancer	4.31e-06	5.44e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MED12—breast cancer	4.27e-06	5.39e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—DPYD—breast cancer	4.27e-06	5.39e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1B1—breast cancer	4.25e-06	5.35e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALDOA—breast cancer	4.21e-06	5.3e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SMAD4—breast cancer	4.18e-06	5.26e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HSP90AA1—breast cancer	4.16e-06	5.25e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NCOA3—breast cancer	4.08e-06	5.15e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HES1—breast cancer	4.08e-06	5.14e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC2A2—breast cancer	4.05e-06	5.11e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NCOR1—breast cancer	4.05e-06	5.11e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NCOA1—breast cancer	4.05e-06	5.11e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF1—breast cancer	4.01e-06	5.05e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—STK11—breast cancer	3.99e-06	5.03e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP19A1—breast cancer	3.99e-06	5.03e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRG1—breast cancer	3.98e-06	5.02e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCG2—breast cancer	3.97e-06	5.01e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CPT1A—breast cancer	3.97e-06	5.01e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTR—breast cancer	3.97e-06	5.01e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—H2AFX—breast cancer	3.95e-06	4.98e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HPGDS—breast cancer	3.9e-06	4.91e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HBA1—breast cancer	3.87e-06	4.88e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERCC2—breast cancer	3.81e-06	4.8e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ACHE—breast cancer	3.78e-06	4.76e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTT1—breast cancer	3.78e-06	4.76e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.75e-06	4.72e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB3—breast cancer	3.73e-06	4.7e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR2—breast cancer	3.72e-06	4.69e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—COMT—breast cancer	3.71e-06	4.68e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTP1—breast cancer	3.69e-06	4.66e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	3.67e-06	4.62e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HMOX1—breast cancer	3.64e-06	4.59e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ITPR1—breast cancer	3.64e-06	4.58e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—breast cancer	3.58e-06	4.52e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP17A1—breast cancer	3.58e-06	4.51e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—breast cancer	3.57e-06	4.5e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO1—breast cancer	3.54e-06	4.46e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS1—breast cancer	3.54e-06	4.46e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCB1—breast cancer	3.5e-06	4.41e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP2D6—breast cancer	3.47e-06	4.38e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR1—breast cancer	3.47e-06	4.37e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMS—breast cancer	3.43e-06	4.33e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIF1A—breast cancer	3.42e-06	4.31e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NCOA2—breast cancer	3.41e-06	4.3e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NCOR1—breast cancer	3.4e-06	4.28e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLA2G4A—breast cancer	3.4e-06	4.28e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTM1—breast cancer	3.4e-06	4.28e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	3.31e-06	4.17e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FASN—breast cancer	3.31e-06	4.17e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CAV1—breast cancer	3.3e-06	4.17e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BCHE—breast cancer	3.29e-06	4.15e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GPX1—breast cancer	3.25e-06	4.1e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC5A5—breast cancer	3.25e-06	4.1e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1A1—breast cancer	3.22e-06	4.06e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ERCC2—breast cancer	3.19e-06	4.02e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NQO1—breast cancer	3.14e-06	3.96e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC2A1—breast cancer	3.14e-06	3.96e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS2—breast cancer	3.11e-06	3.92e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOTCH1—breast cancer	3.08e-06	3.88e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP3A4—breast cancer	3.06e-06	3.86e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1B1—breast cancer	3.01e-06	3.79e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APC—breast cancer	3.01e-06	3.79e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KIT—breast cancer	3.01e-06	3.79e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—breast cancer	3e-06	3.78e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	2.99e-06	3.77e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGF—breast cancer	2.98e-06	3.75e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HSP90AA1—breast cancer	2.95e-06	3.72e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NCOA1—breast cancer	2.87e-06	3.62e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—STK11—breast cancer	2.83e-06	3.57e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP19A1—breast cancer	2.83e-06	3.57e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—breast cancer	2.83e-06	3.57e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CAV1—breast cancer	2.77e-06	3.49e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT2—breast cancer	2.75e-06	3.47e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CD—breast cancer	2.65e-06	3.34e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.64e-06	3.33e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—COMT—breast cancer	2.63e-06	3.32e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTP1—breast cancer	2.62e-06	3.3e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SERPINE1—breast cancer	2.62e-06	3.3e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HMOX1—breast cancer	2.58e-06	3.26e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ITPR1—breast cancer	2.58e-06	3.25e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CG—breast cancer	2.52e-06	3.18e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS3—breast cancer	2.5e-06	3.15e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMS—breast cancer	2.43e-06	3.07e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM1—breast cancer	2.41e-06	3.03e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NCOR1—breast cancer	2.41e-06	3.03e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLA2G4A—breast cancer	2.41e-06	3.03e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MDM2—breast cancer	2.37e-06	2.99e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RAF1—breast cancer	2.36e-06	2.98e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—breast cancer	2.34e-06	2.95e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CB—breast cancer	2.31e-06	2.91e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTOR—breast cancer	2.31e-06	2.91e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPX1—breast cancer	2.3e-06	2.91e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—breast cancer	2.3e-06	2.9e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1A1—breast cancer	2.28e-06	2.88e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ERCC2—breast cancer	2.26e-06	2.85e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CD—breast cancer	2.22e-06	2.79e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—breast cancer	2.19e-06	2.76e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1B—breast cancer	2.16e-06	2.73e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—breast cancer	2.13e-06	2.68e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NOS3—breast cancer	2.09e-06	2.64e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—breast cancer	2.04e-06	2.58e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1A—breast cancer	2e-06	2.52e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—breast cancer	1.99e-06	2.51e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CAV1—breast cancer	1.96e-06	2.47e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CB—breast cancer	1.93e-06	2.43e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SRC—breast cancer	1.85e-06	2.33e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CG—breast cancer	1.79e-06	2.25e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—breast cancer	1.78e-06	2.25e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK3—breast cancer	1.7e-06	2.15e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—breast cancer	1.67e-06	2.1e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—breast cancer	1.66e-06	2.09e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—breast cancer	1.65e-06	2.08e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—breast cancer	1.62e-06	2.04e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CD—breast cancer	1.57e-06	1.98e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—breast cancer	1.55e-06	1.95e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—breast cancer	1.53e-06	1.93e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NOS3—breast cancer	1.48e-06	1.87e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—breast cancer	1.41e-06	1.77e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CB—breast cancer	1.37e-06	1.73e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—breast cancer	1.36e-06	1.71e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—breast cancer	1.3e-06	1.64e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—breast cancer	1.25e-06	1.57e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—breast cancer	1.18e-06	1.49e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—breast cancer	1.18e-06	1.48e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—breast cancer	1.15e-06	1.45e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—breast cancer	9.62e-07	1.21e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—breast cancer	8.35e-07	1.05e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—breast cancer	6.82e-07	8.6e-06	CbGpPWpGaD
